IU218 - Real-World Success with Lenire

Abstract:
The Lenire device, combining sound therapy and tongue stimulation, offers an innovative solution for tinnitus management. A U.S. review of 220 patients at the Alaska Hearing and Tinnitus Center showed 91.5% of those with moderate to severe tinnitus experienced significant improvement, averaging a 27.8-point reduction in Tinnitus Handicap Inventory scores after 12 weeks, with no serious adverse events. Supported by the TENT-A3 clinical trial, Lenire’s safety and efficacy make it a promising option for addressing tinnitus across diverse populations, offering hope for improved quality of life and reduced disability burden for those affected by this challenging condition.

Summary:
Tinnitus, a persistent perception of sound in the absence of an external source, poses a significant challenge to patients and healthcare providers. While traditional management approaches focus on sound therapy and psychological interventions, bimodal neuromodulation using the Lenire device has emerged as a promising, evidence-based treatment for tinnitus. Lenire combines sound therapy with electrical tongue stimulation, a novel approach designed to modulate auditory and somatosensory pathways associated with tinnitus perception. Key findings from two pivotal studies showcase the efficacy and real-world benefits of Lenire.

Study 1: Real-World Outcomes in a U.S. Clinical Setting
A single-arm retrospective chart review assessed the real-world outcomes of the Lenire device among 220 tinnitus patients treated at the Alaska Hearing and Tinnitus Center. This study represents the first U.S.-based evaluation of patients following Lenire’s FDA approval as the first device of its kind for the treatment of tinnitus. The primary endpoint focused on the responder rate and the mean change in Tinnitus Handicap Inventory (THI) scores after approximately 12 weeks of treatment. A responder was defined as achieving a THI improvement of greater than seven points, the minimal clinically important difference (MCID) for tinnitus.
Of the 212 patients with complete data, 91.5% (95% CI: 86.9%, 94.5%) achieved a clinically significant reduction in their THI scores, with an average improvement of 27.8 ± 1.3 points. These results underscore Lenire’s potential to deliver meaningful symptom relief in a real-world clinical setting. Importantly, no device-related serious adverse events were reported, affirming the safety of this treatment modality. The study highlights Lenire’s role in addressing moderate to severe tinnitus, demonstrating consistent clinical benefit based on established MCID thresholds.

Study 2: Efficacy with TENT-A3
The TENT-A3 clinical trial further validates Lenire’s effectiveness, offering robust data from a controlled study environment. This research builds on earlier trials, establishing bimodal neuromodulation as a significant advancement in tinnitus management. TENT-A3 evaluated the effects of sound therapy combined with electrical tongue stimulation, focusing on patient-reported outcomes such as THI scores and overall quality of life. The trial reinforced Lenire’s efficacy in reducing tinnitus severity, with improvements comparable to or exceeding previous benchmarks in clinical tinnitus research.

The combined findings of these studies establish Lenire as a transformative option for tinnitus patients. Real-world evidence from U.S.-based clinics aligns with controlled trial outcomes, confirming that bimodal neuromodulation can significantly reduce tinnitus severity with a high responder rate and minimal risk of adverse events. This dual approach of sound therapy and tongue stimulation represents an innovative paradigm, addressing underlying neurological mechanisms and providing substantial, measurable improvements in patient outcomes.

As a non-invasive, patient-friendly solution, Lenire offers new hope for individuals struggling with tinnitus. These findings underscore its potential to become a standard of care, enabling clinicians to deliver effective, evidence-based treatment to a wider population of patients.

Brief Summary of Clinical Takeaways:
The clinical takeaway for this session is that the real-world U.S. data and controlled trials demonstrate, for Lenire, show its efficacy, with 91.5% of patients achieving significant THI score reductions and no serious adverse events. Lenire offers a safe, innovative, and effective treatment for tinnitus sufferers.

Course Content Disclosure: This course will discuss a specific product or service offered by the exhibiting company leading this presentation with limited to no information about like products or services.